Pre-clinical anticancer drugs screening: perspectives from emerging models of glioma biology
https://doi.org/10.4081/dts.2011.e1
Submitted: 8 December 2010
Accepted: 8 December 2010
Published: 28 December 2010
Accepted: 8 December 2010
Abstract Views: 696
PDF: 450
HTML: 299
HTML: 299
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supporting Agencies
Research in author's laboratory is supported by grants from the Swedish Research Council and the Karolinska Institute.Yakisich, J. S. (2010). Pre-clinical anticancer drugs screening: perspectives from emerging models of glioma biology. Drugs and Therapy Studies, 1(1), e1. https://doi.org/10.4081/dts.2011.e1
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Download data is not yet available.
Citations
